Muscular Dystrophy Association
National Headquarters
3300 E. Sunrise Drive
Tucson
Arizona
85718
United States
Tel: 800-344-4863
Website: http://www.mda.org/
103 articles about Muscular Dystrophy Association
-
Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference
2/15/2024
The Muscular Dystrophy Association announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference, where she will address the world’s leaders in neuromuscular disease research and care.
-
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
10/26/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
-
Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
10/18/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
-
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
6/27/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
-
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
6/20/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc),for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
-
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy Announce Collaborative Project to Focus on Re-Dosing Gene Therapy in Duchenne Muscular Dystrophy
6/15/2023
CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy, announced a collaborative clinical trial grant to test repurposing of the FDA-approved drug Vyvgart, for its potential ability to reduce antibodies to adeno-associated virus in Duchenne muscular dystrophy patients.
-
Muscular Dystrophy Association Tribute Awards in Washington D.C. Honor Diana X. Bharucha-Goebel, M.D., R. Rodney Howell, M.D., Paul Robertson, Jeni Stepanek, Ph.D., Janet Woodcock, M.D.
5/11/2023
Muscular Dystrophy Association Tribute Awards will be held in Washington D.C. to honor.
-
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
4/25/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) associated with mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).
-
Muscular Dystrophy Association Announces Recipient of 2023 MDA Legacy Award for Achievement in Clinical Research is Merit Cudkowicz, MD, MSC, Renowned Neurologist and Clinical Researcher in ALS
3/6/2023
The Muscular Dystrophy Association announced Merit Cudkowicz, MD, MSC, a renowned neurologist and clinical researcher in ALS from Massachusetts General Hospital, will receive the 2023 MDA Legacy Award for Achievement in Clinical Research.
-
Muscular Dystrophy Association Celebrates FDA Approval of Skyclarys, First Ever Treatment for Friedreich’s Ataxia from Reata Pharmaceuticals
3/1/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Omaveloxolone (Skyclarys), the first ever treatment for Friedreich’s Ataxia (FA), a rare neuromuscular disease on Rare Disease Day today, February 28.
-
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
1/17/2023
The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).
-
Muscular Dystrophy Association Celebrates the Approval of Relyvrio from Amylyx for the Treatment of ALS
9/30/2022
The Muscular Dystrophy Association celebrates the US Food and Drug Administration approval of sodium phenylbutyrate/taurursodiol for the treatment of amyotrophic lateral sclerosis, on September 29.
-
Muscular Dystrophy Association Gathers Global Leaders at Annual Conference, the Largest Convening in the Field of Neuromuscular Disease Research & Care in the World
2/9/2022
Bringing together more than 1,200 attendees both in-person and virtually, MDA leads the way as the only voluntary health organization in the neuromuscular disease space to combine the latest in research, clinical care, treatment and management, with the goal of transforming care through innovation and allowing people living with neuromuscular disease to live longer lives. [09-February-2022]
-
Muscular Dystrophy Association Awards 18 Grants Totaling Over $1.6 Million for Development Grants and Idea Awards
10/28/2021
The Muscular Dystrophy Association announced the awarding of 18 new MDA grants totaling over $1.6 million toward neuromuscular disease research.
-
Play with a Pro! Nyheim Hines, NFL Indianapolis Colts Running Back Joins MDA Let's Play Gaming Community on June 12 from 7-8pm for Game Night
6/1/2021
Viewers and players can expect an exciting evening of programming, including gameplay from popular titles Among Us and Jackbox games, with kids and families living with muscular dystrophy, ALS, and related neuromuscular diseases, coming together to build community.
-
Muscular Dystrophy Association Announces Community Education & Fundraising Events To Find a Cure for ALS
4/26/2021
The Muscular Dystrophy Association announced programming and fundraising events in support of people living with Amyotrophic Lateral Sclerosis throughout ALS Awareness Month in May, and participation in Major League Baseball's designation of Lou Gehrig's Day on June 2, in the effort to cure the disease.
-
Registration opens for Virtual MDA Summer Camp for Children with Neuromuscular Diseases
4/21/2021
The Muscular Dystrophy Association announced the opening of registration for its virtual MDA Summer Camp for children ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.
-
Golf Events Bring Lifesaving Funds for Research & Care for 300,000+ Families Living with Disabilities Including Muscular Dystrophy, ALS and Over 40 Related Neuromuscular Diseases
3/22/2021
Registration is open for golf events at premier championship courses including the Arizona Biltmore Golf Club, Eugene Country Club, The Golf Club at Newcastle, and Western Lakes Golf Club, in support of MDA
-
Muscular Dystrophy Association to Roll Out the 39th Annual MDA Shamrocks Campaign with Retailers Nationwide
2/16/2021
Thousands of retailers nationwide support MDA's fundraising campaign to transform the lives of people living with muscular dystrophy, ALS and related neuromuscular diseases throughout February and March.
-
MDA Names Kristine Welker as Chief of Staff
1/13/2021
The Muscular Dystrophy Association announced it has appointed Kristine Welker to the newly created role of chief of staff.